Put our knowledge and experience to work for you.
Experience and success go hand in hand.
ATON Partners invests in early medical device and diagnostic technologies with characterstics that include:• True Innovation
• Market Disruption
• Cost Effectiveness
• Improved Patient Outcomes
Sullivan and Levangie led the emergence of Cytyc Corporation as the pre-eminent company in delivering innovative solutions for women’s health problems. This included the introduction of the ThinPrep Pap Test System, the NovaSure Endometrial Ablation System, the MammoSite Targeted Radiation System, and Fetal Fibronectin Testing for pre-term delivery. Each proved to be innovative, disruptive, cost effective, standard-of- care-changing technologies. Cytyc was acquired by Hologic, Inc. in 2007.
Sullivan and Levangie led the investment and development of the DaisyClip Permanent Birth-Control Device—a groundbreaking approach to non-invasive tubal occlusion with potential market disrupting features. DaisyClip was acquired by Hologic, Inc. in June, 2012.
Sullivan and Levangie most recently led the investment and development of the Bloodhound Fully Integrated Hematology System—a highly disruptive technology focused on revolutionizing an entrenched standard of care in a 1 billion annual test market in hematology. The Bloodhound System was acquired by Roche Diagnostics in July, 2013.
ATON Partners will leverage their decades long experience with inventors and entrepreneurs to develop, test, and commercialize similar game-changing medical device and diagnostics technologies.